AMPK Signalling and Defective Energy Metabolism in Amyotrophic Lateral Sclerosis
- PMID: 26202426
- DOI: 10.1007/s11064-015-1665-3
AMPK Signalling and Defective Energy Metabolism in Amyotrophic Lateral Sclerosis
Abstract
Amyotrophic lateral sclerosis (ALS) is caused by selective loss of upper and lower motor neurons by complex mechanisms that are incompletely understood. Motor neurons are large, highly polarised and excitable cells with unusually high energetic demands to maintain resting membrane potential and propagate action potentials. This leads to higher ATP consumption and mitochondrial metabolism in motor neurons relative to other cells. Here, we review increasing evidence that defective energy metabolism and homeostasis contributes to selective vulnerability and degeneration of motor neurons in ALS. Firstly, we provide a brief overview of major energetic pathways in the CNS, including glycolysis, oxidative phosphorylation and the AMP-activated protein kinase (AMPK) signalling pathway, while highlighting critical metabolic interactions between neurons and astrocytes. Next, we review evidence from ALS patients and transgenic mutant SOD1 mice for weight loss, hypermetabolism, hyperlipidemia and mitochondrial dysfunction in disease onset and progression. Genetic and therapeutic modifiers of energy metabolism in mutant SOD1 mice will also be summarised. We also present evidence that additional ALS-linked proteins, TDP-43 and FUS, lead to energy disruption and mitochondrial defects in motor neurons. Lastly, we review emerging evidence including our own that dysregulation of the AMPK signalling cascade in motor neurons is an early and common event in ALS pathogenesis. We suggest that an imbalance in energy metabolism should be considered an important factor in both progression and potential treatment of ALS.
Keywords: ALS; AMPK; Energy; Metabolism; SOD1; TDP-43.
Similar articles
-
Superoxide dismutase 1 mutation in a cellular model of amyotrophic lateral sclerosis shifts energy generation from oxidative phosphorylation to glycolysis.Neurobiol Aging. 2014 Jun;35(6):1499-509. doi: 10.1016/j.neurobiolaging.2013.11.025. Epub 2013 Dec 3. Neurobiol Aging. 2014. PMID: 24439480
-
"Preconditioning" with latrepirdine, an adenosine 5'-monophosphate-activated protein kinase activator, delays amyotrophic lateral sclerosis progression in SOD1(G93A) mice.Neurobiol Aging. 2015 Feb;36(2):1140-50. doi: 10.1016/j.neurobiolaging.2014.09.022. Epub 2014 Sep 26. Neurobiol Aging. 2015. PMID: 25443289
-
Mutant TDP-43 deregulates AMPK activation by PP2A in ALS models.PLoS One. 2014 Mar 4;9(3):e90449. doi: 10.1371/journal.pone.0090449. eCollection 2014. PLoS One. 2014. PMID: 24595038 Free PMC article.
-
What is "Hyper" in the ALS Hypermetabolism?Mediators Inflamm. 2017;2017:7821672. doi: 10.1155/2017/7821672. Epub 2017 Sep 7. Mediators Inflamm. 2017. PMID: 29081604 Free PMC article. Review.
-
Altered Metabolic Homeostasis in Amyotrophic Lateral Sclerosis: Mechanisms of Energy Imbalance and Contribution to Disease Progression.Neurodegener Dis. 2016;16(5-6):382-97. doi: 10.1159/000446502. Epub 2016 Jul 12. Neurodegener Dis. 2016. PMID: 27400276 Review.
Cited by
-
Phosphoregulation on mitochondria: Integration of cell and organelle responses.CNS Neurosci Ther. 2019 Jul;25(7):837-858. doi: 10.1111/cns.13141. Epub 2019 Apr 25. CNS Neurosci Ther. 2019. PMID: 31025544 Free PMC article. Review.
-
CK and LRRK2 Involvement in Neurodegenerative Diseases.Int J Mol Sci. 2024 Oct 30;25(21):11661. doi: 10.3390/ijms252111661. Int J Mol Sci. 2024. PMID: 39519213 Free PMC article. Review.
-
Mapping the Evidence for Measuring Energy Expenditure and Indicating Hypermetabolism in Motor Neuron Disease: A Scoping Review.Nutr Rev. 2025 May 1;83(5):943-960. doi: 10.1093/nutrit/nuae118. Nutr Rev. 2025. PMID: 39375842 Free PMC article.
-
Sephin1 suppresses ER stress-induced cell death by inhibiting the formation of PP2A holoenzyme.Cell Death Dis. 2025 Feb 19;16(1):117. doi: 10.1038/s41419-025-07450-1. Cell Death Dis. 2025. PMID: 39971896 Free PMC article.
-
α1-Adrenergic Receptors: Insights into Potential Therapeutic Opportunities for COVID-19, Heart Failure, and Alzheimer's Disease.Int J Mol Sci. 2023 Feb 20;24(4):4188. doi: 10.3390/ijms24044188. Int J Mol Sci. 2023. PMID: 36835598 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous